Plain-English translation of NCT04649242 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called rimegepant to see if it can safely treat migraine attacks in children and teens ages 6 to 17. About 2,100 young people will take either rimegepant or a placebo (a pill with no active medicine) when they have a migraine, and researchers will measure whether the medication works better than placebo at relieving pain and other migraine symptoms. This is a Phase 3 trial, meaning the medication has already been tested in smaller groups and now needs to be tested in a larger, more diverse group to confirm it's safe and effective.
Migraines in children and teens can be very painful and disruptive to school and daily life, but there are limited treatment options designed specifically for young people. This trial aims to determine whether this new medication could offer a safe, effective way to quickly relieve migraine attacks in this age group.
You likely qualify if…
You likely don't qualify if…
You would come to the study clinic multiple times to be screened and enrolled. Once enrolled, you would take either the new medication or a placebo (both as a dissolving tablet) when you have a moderate or severe migraine attack. The study team would ask you to record information about your migraine symptoms and how the treatment worked. You would also have blood tests and check-in visits with the research team throughout the study to monitor your safety and how well the medication is working.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States